MTHFR A1298C Mutation Explained

A1298C is the second MTHFR variant — the one that shows up on your report underneath C677T, usually with less explanation and considerably more speculation attached to it online.

It is worth understanding on its own terms, because A1298C is not simply "C677T but different." It is a weaker variant, in a different part of the protein, with a thinner evidence base and a distinctive inheritance quirk that changes which genotype combinations are even biologically possible.

What A1298C is, technically

A1298C is a single-nucleotide change in exon 7 of the MTHFR gene. In current nomenclature it is c.1286A>C, producing the protein change p.Glu429Ala — a glutamate replaced by an alanine at position 429.

That position matters. C677T sits in the enzyme's catalytic domain — the business end that performs the chemistry. A1298C sits in the regulatory domain, the part that controls the enzyme's activity rather than doing the work directly. This is one reason the two variants behave differently.

The A1298C polymorphism is associated with reduced MTHFR enzyme activity, with the glutamate-to-alanine substitution reducing enzyme activity by around 40%. That reduction is real, but it is consistently described as being to a lesser extent than C677T.

How common is A1298C?

Common, though the distribution differs markedly from C677T and varies substantially by ancestry.

The prevalence of the homozygous CC variant genotype ranges from roughly 7 to 12% in Europe, 4 to 5% in Hispanic populations, and 1 to 4% in Asian populations. Heterozygote frequencies are considerably higher again — carrying one copy is thoroughly unremarkable.

The linkage disequilibrium quirk

This is the part almost nobody explains, and it is genuinely important for interpreting a combined result.

C677T and A1298C are in linkage disequilibrium with each other. In plain terms: they do not assort independently. Because of how these two variants sit on the same chromosome and how they have been inherited through human history, certain combinations are common and others are vanishingly rare.

Specifically, a combination of both variants is usually seen only in individuals who are compound heterozygotes in trans — meaning one variant on each of the two chromosome copies. Homozygosity for one variant combined with heterozygosity for the other is rare.

What that means practically:

• Compound heterozygous (one C677T + one A1298C) is a common, expected combination. It is the normal way to end up with both variants.
• "Triple variant" genotypes — homozygous for one variant and heterozygous for the other — are genuinely rare, because they require an unusual chromosomal arrangement.
• Homozygous for both (four variant alleles) is essentially not observed.

If you see an online source describing homozygous C677T and homozygous A1298C as a common and dangerous combination, that source does not understand the genetics.

What the ACMG says about A1298C

Read that carefully, because it is remarkable. Being homozygous for A1298C — having two copies, the "worst case" for this variant — is on the list of genotypes the professional body considers unlikely to be clinically significant.

The triple variant genotypes get a slightly different treatment. The guideline notes there is theoretical reason to be concerned that rare individuals with triple variant genotypes may have resulting clinical risks, although it explicitly describes that as currently speculative. "Theoretical" and "speculative" are not endorsements. They are the language of an open question, not an established risk.

What about the disease associations?

A1298C has been investigated for associations with a long list of conditions — cardiovascular disease, pregnancy loss, various cancers, neurological conditions. The pattern in the literature is consistent and unflattering.

Cancer

A1298C has been investigated in several studies, but the results are less convincing than for C677T. Given that C677T's own cancer associations are inconsistent, "less convincing than C677T" is a low bar to fall below. There is some interesting research on MTHFR genotype and response to the chemotherapy drug 5-fluorouracil, but the clinical relevance of these findings still requires reproduction before clinical consequences can be drawn. That is not something a consumer report can act on.

Cardiovascular and thrombotic risk

Studies have shown that the MTHFR C677T and A1298C polymorphisms are not independently associated with increased risk of venous thromboembolism. The same guidelines that decline to recommend C677T testing apply equally to A1298C.

Combined enzyme effects

There is one nuance worth reporting fairly. Some research has suggested that while a single MTHFR variant in isolation may not substantially reduce enzyme activity, the compound heterozygous state can produce a more meaningful decrease alongside elevated homocysteine. That finding exists in the literature. But it sits alongside the ACMG's explicit assessment that this same compound heterozygous genotype is unlikely to be clinically significant — and when a professional guideline body and an individual study disagree, the guideline is the safer guide for someone making personal health decisions.

A1298C vs C677T: the honest comparison

The pattern is clear. A1298C is the milder variant on essentially every axis, and the professional consensus is the same for both: not worth testing routinely, and not a basis for changing your folate supplementation.

What to actually do if you have A1298C

The same proportionate response that applies to C677T applies here, with even less urgency:

• Eat enough folate. Leafy greens, legumes, citrus, fortified grains. The folate cycle needs folate; that is the whole lever.
• If pregnant or planning pregnancy, take standard folic acid supplementation. Guidance specifically says not to adjust preventive folic acid dosing for neural tube defect prevention based on MTHFR results.
• If you want to know whether your methylation is working, measure homocysteine. It reflects your actual biochemistry, not a single genetic input to it.
• Be skeptical of A1298C-specific supplement protocols. The variant with less evidence than the variant that already has weak evidence is not a foundation for a complex intervention.

The bottom line

A1298C reduces MTHFR enzyme activity modestly. It is common, particularly in European populations. Its disease associations are weaker and less replicated than C677T's, and the ACMG names homozygosity for it as unlikely to be clinically significant.

If you have it: eat your greens, take standard folate if you are pregnant, and get on with your life. That is not a dismissive answer. It is the answer the evidence supports.